## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 1.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($473.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20260101T110901 | Neutral | Relevance: 100%
- Virginia Retirement Systems et al significantly reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by selling 137,900 shares, decreasing its holdings by 71.1%. This divestment is part of broader insider selling activity, with COO Michael Benkowitz and other insiders selling a substantial number of shares recently. Despite this, United Therapeutics reported a quarterly EPS beat and maintains a "Moderate Buy" consensus rating from analysts.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 23 ($13.76M) |
| Sells | 63 ($39.72M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $40M sold (63 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.4x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($39.7M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.5B |
| Beta | 0.86 |
| 52W Range | $266.98 - $519.99 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.4 |
| Current P/E | 18.3 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.1% (minimal 5-day change). Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.36x) but short-term weakness (below SMA20). MACD histogram bearish (-3.06), momentum weakening. RSI neutral at 53. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.06% (CS: 21) | Neutral |
| RSI_14 | 53.1 | Neutral |
| MACD Histogram | -3.06 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.358x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $496.72
- **Stop Loss:** $473.12 (4.8% risk)
- **Target:** $520.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $30,299.92
- **Portfolio %:** 30.30%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*